196 related articles for article (PubMed ID: 28464785)
1. Major Developments in the Design of Inhibitors along the Kynurenine Pathway.
Jacobs KR; Castellano-Gonzalez G; Guillemin GJ; Lovejoy DB
Curr Med Chem; 2017; 24(23):2471-2495. PubMed ID: 28464785
[TBL] [Abstract][Full Text] [Related]
2. Challenges and Opportunities in the Discovery of New Therapeutics Targeting the Kynurenine Pathway.
Dounay AB; Tuttle JB; Verhoest PR
J Med Chem; 2015 Nov; 58(22):8762-82. PubMed ID: 26207924
[TBL] [Abstract][Full Text] [Related]
3. Abnormal kynurenine pathway of tryptophan catabolism in cardiovascular diseases.
Song P; Ramprasath T; Wang H; Zou MH
Cell Mol Life Sci; 2017 Aug; 74(16):2899-2916. PubMed ID: 28314892
[TBL] [Abstract][Full Text] [Related]
4. The kynurenine pathway as a therapeutic target in cognitive and neurodegenerative disorders.
Stone TW; Darlington LG
Br J Pharmacol; 2013 Jul; 169(6):1211-27. PubMed ID: 23647169
[TBL] [Abstract][Full Text] [Related]
5. Genetic alterations affecting the genes encoding the enzymes of the kynurenine pathway and their association with human diseases.
Boros FA; Bohár Z; Vécsei L
Mutat Res Rev Mutat Res; 2018; 776():32-45. PubMed ID: 29807576
[TBL] [Abstract][Full Text] [Related]
6. The inhibition of the kynurenine pathway prevents behavioral disturbances and oxidative stress in the brain of adult rats subjected to an animal model of schizophrenia.
Réus GZ; Becker IRT; Scaini G; Petronilho F; Oses JP; Kaddurah-Daouk R; Ceretta LB; Zugno AI; Dal-Pizzol F; Quevedo J; Barichello T
Prog Neuropsychopharmacol Biol Psychiatry; 2018 Feb; 81():55-63. PubMed ID: 29030243
[TBL] [Abstract][Full Text] [Related]
7. Involvement of Indoleamine-2,3-Dioxygenase and Kynurenine Pathway in Experimental Autoimmune Encephalomyelitis in Mice.
Zarzecki MS; Cattelan Souza L; Giacomeli R; Silva MRP; Prigol M; Boeira SP; Jesse CR
Neurochem Res; 2020 Dec; 45(12):2959-2977. PubMed ID: 33040279
[TBL] [Abstract][Full Text] [Related]
8. The Kynurenine Pathway as a Potential Target for Neuropathic Pain Therapy Design: From Basic Research to Clinical Perspectives.
Ciapała K; Mika J; Rojewska E
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681715
[TBL] [Abstract][Full Text] [Related]
9. Differential kynurenine pathway metabolism in highly metastatic aggressive breast cancer subtypes: beyond IDO1-induced immunosuppression.
Heng B; Bilgin AA; Lovejoy DB; Tan VX; Milioli HH; Gluch L; Bustamante S; Sabaretnam T; Moscato P; Lim CK; Guillemin GJ
Breast Cancer Res; 2020 Oct; 22(1):113. PubMed ID: 33109232
[TBL] [Abstract][Full Text] [Related]
10. The Kynurenine Pathway and Kynurenine 3-Monooxygenase Inhibitors.
Hughes TD; Güner OF; Iradukunda EC; Phillips RS; Bowen JP
Molecules; 2022 Jan; 27(1):. PubMed ID: 35011505
[TBL] [Abstract][Full Text] [Related]
11. Substrate and inhibitor specificity of kynurenine monooxygenase from Cytophaga hutchinsonii.
Phillips RS; Anderson AD; Gentry HG; Güner OF; Bowen JP
Bioorg Med Chem Lett; 2017 Apr; 27(8):1705-1708. PubMed ID: 28302400
[TBL] [Abstract][Full Text] [Related]
12. Development of a series of aryl pyrimidine kynurenine monooxygenase inhibitors as potential therapeutic agents for the treatment of Huntington's disease.
Toledo-Sherman LM; Prime ME; Mrzljak L; Beconi MG; Beresford A; Brookfield FA; Brown CJ; Cardaun I; Courtney SM; Dijkman U; Hamelin-Flegg E; Johnson PD; Kempf V; Lyons K; Matthews K; Mitchell WL; O'Connell C; Pena P; Powell K; Rassoulpour A; Reed L; Reindl W; Selvaratnam S; Friley WW; Weddell DA; Went NE; Wheelan P; Winkler C; Winkler D; Wityak J; Yarnold CJ; Yates D; Munoz-Sanjuan I; Dominguez C
J Med Chem; 2015 Feb; 58(3):1159-83. PubMed ID: 25590515
[TBL] [Abstract][Full Text] [Related]
13. The discovery of potent and selective kynurenine 3-monooxygenase inhibitors for the treatment of acute pancreatitis.
Liddle J; Beaufils B; Binnie M; Bouillot A; Denis AA; Hann MM; Haslam CP; Holmes DS; Hutchinson JP; Kranz M; McBride A; Mirguet O; Mole DJ; Mowat CG; Pal S; Rowland P; Trottet L; Uings IJ; Walker AL; Webster SP
Bioorg Med Chem Lett; 2017 May; 27(9):2023-2028. PubMed ID: 28336141
[TBL] [Abstract][Full Text] [Related]
14. Indoleamine 2,3-dioxygenase 2 (IDO2) and the kynurenine pathway: characteristics and potential roles in health and disease.
Fatokun AA; Hunt NH; Ball HJ
Amino Acids; 2013 Dec; 45(6):1319-29. PubMed ID: 24105077
[TBL] [Abstract][Full Text] [Related]
15. Effect of indoleamine dioxygenase-1 deficiency and kynurenine pathway inhibition on murine cerebral malaria.
Miu J; Ball HJ; Mellor AL; Hunt NH
Int J Parasitol; 2009 Feb; 39(3):363-70. PubMed ID: 19000912
[TBL] [Abstract][Full Text] [Related]
16. Assessing and Modulating Kynurenine Pathway Dynamics in Huntington's Disease: Focus on Kynurenine 3-Monooxygenase.
Sathyasaikumar KV; Breda C; Schwarcz R; Giorgini F
Methods Mol Biol; 2018; 1780():397-413. PubMed ID: 29856028
[TBL] [Abstract][Full Text] [Related]
17. Structural basis of kynurenine 3-monooxygenase inhibition.
Amaral M; Levy C; Heyes DJ; Lafite P; Outeiro TF; Giorgini F; Leys D; Scrutton NS
Nature; 2013 Apr; 496(7445):382-5. PubMed ID: 23575632
[TBL] [Abstract][Full Text] [Related]
18. Novel indoleamine 2,3-dioxygenase-1 inhibitors from a multistep in silico screen.
Smith JR; Evans KJ; Wright A; Willows RD; Jamie JF; Griffith R
Bioorg Med Chem; 2012 Feb; 20(3):1354-63. PubMed ID: 22112538
[TBL] [Abstract][Full Text] [Related]
19. Tryptophan metabolism along the kynurenine pathway in diet-induced and genetic hypercholesterolemic rabbits.
Allegri G; Ragazzi E; Costa CV; Caparrotta L; Biasiolo M; Comai S; Bertazzo A
Clin Chim Acta; 2004 Dec; 350(1-2):41-9. PubMed ID: 15530458
[TBL] [Abstract][Full Text] [Related]
20. Rational design of indoleamine 2,3-dioxygenase inhibitors.
Röhrig UF; Awad L; Grosdidier A; Larrieu P; Stroobant V; Colau D; Cerundolo V; Simpson AJ; Vogel P; Van den Eynde BJ; Zoete V; Michielin O
J Med Chem; 2010 Feb; 53(3):1172-89. PubMed ID: 20055453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
